


PI4KIIIbeta-IN-10

Cat. No.:	HY-100198		
CAS No.:	1881233-39-1		
Molecular Formula:	C ₂₂ H ₂₅ N ₃ O ₅ S ₂		
Molecular Weight:	475.58		
Target:	PI4K; PI3K		
Pathway:	PI3K/Akt/mTOR		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 125 mg/mL (262.84 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
Preparing Stock Solutions	1 mM	2.1027 mL	10.5135 mL	21.0270 mL
	5 mM	0.4205 mL	2.1027 mL	4.2054 mL
	10 mM	0.2103 mL	1.0513 mL	2.1027 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	<ol style="list-style-type: none"> Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.26 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.26 mM); Clear solution Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.26 mM); Clear solution 			

BIOLOGICAL ACTIVITY

Description	PI4KIIIbeta-IN-10 is a potent PI4KIIIβ inhibitor with an IC ₅₀ of 3.6 nM.			
IC₅₀ & Target	PI4KIIIβ 3.6 nM (IC ₅₀)	PI4KIIIα 3 μM (IC ₅₀)	PI3Kδ 720 nM (IC ₅₀)	PI3KC2γ 1 μM (IC ₅₀)
	PI3Kα 10 μM (IC ₅₀)	PI3Kγ 20 μM (IC ₅₀)		

In Vitro

PI4KIIIbeta-IN-10 (Compound 10) is a potent PI4KIIIβ inhibitor with very minor off-target inhibition of PI4KIIIβ related lipid kinases. PI4KIIIbeta-IN-10 shows weak inhibition of PI3KC2γ (IC₅₀ ~1 μM), PI3Kα (~10 μM), and PI4KIIIα (~3 μM), and <20% inhibition at concentrations up to 20 μM for PI4K2α, PI4K2β, and PI3Kβ^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Kinase Assay ^[1]

Lipid kinase assays are preformed using recombinant enzyme, phosphoinositides and γ³²P-ATP in a membrane capture assay. Each inhibitor (e.g., PI4KIIIbeta-IN-10) is diluted into 10% DMSO and kinase assay buffer. Upon completion of the reaction, 4 μL is spotted onto 0.2 μm nitrocellulose. The membrane is dried for 5 minutes under a heat lamp followed by 1×30 second wash and 6×5 min washes in 1M NaCl /1% Phosphoric Acid. The membrane is dried for 20 minutes under a heat lamp followed by overnight exposure to a phosphor screen and phosphorimaging followed on a Typhoon 9500. Intensities are quantified using SPOT. Specifications for each enzyme follow. L-α-Phosphatidylinositol and DOPS:DOPC lipids are sonicated in water to generate 1mg/mL PI:DOPS:DOPC. Reaction is set-up as follows 1) kinase assay buffer, PI:DOPS:DOPC, BSA and PI4KIIIβ, are combined in a total volume of 10 μL (2.5x solution); 2) 5 μL of inhibitor solution is added (5x solution) and incubated with enzyme mixture for 15 minutes; 3) 10 μL cold ATP and γ³²P-ATP are added (2.5x solution) to initiate the reaction which ran for 30 minutes. Final conditions are as follows: 20 mM Bis-Tris Propane pH 7.5, 10 mM MgCl₂, 0.075 mM Triton X-100, 0.5 mM EGTA, 1 mM DTT, 100 μM PI, 500 ng/μL BSA, 2.5 nM PI4KIIIβ, 2% DMSO, 10 μM ATP and 1 uCi γ³²P-ATP^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Nat Immunol. 2022 Nov 28.
- J Extracell Vesicles. 2022 Jun;11(6):e12233.
- Nat Chem Biol. 2022 Jul 4.
- Autophagy. 2019 Jul;15(7):1214-1233.
- EMBO J. 2022 Nov 21;e112677.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Rutaganira FU, et al. Design and Structural Characterization of Potent and Selective Inhibitors of Phosphatidylinositol 4 Kinase IIIβ. J Med Chem. 2016 Mar 10;59(5):1830-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA